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IL23R Arg381Gln is associated
with childhood onset inflammatory
bowel disease in Scotland
The discovery of NOD2/CARD15 as the first
susceptibility gene in Crohn’s disease has
contributed significantly to a fundamental
change in the direction of basic research in
inflammatory bowel disease (IBD), triggering
renewed interest in the integrity of the innate
immune response in IBD and appropriate
orchestration of a subsequent adaptive
immune response.1 2 More widely, in all com-
plex diseases this finding in 2001 provided a
much welcomed and needed proof of principle
for non-parametric linkage analysis.
Another study with major implications for
the pathogenesis of Crohn’s disease as well as
for investigation of all complex disorders has
recently been published.3 The North American
consortium performed an association study
testing 308 332 markers spanning the entire
genome in 567 patients with ileal Crohn’s
disease and 571 controls of non-Jewish
European ancestry. Of the three markers
reported to retain significance after stringent
Bonferroni correction, two were located in the
NOD2/CARD15 gene. The third marker
(rs11209026) was a non-synonymous variant
in the interleukin-23 receptor (IL23R) gene on
chromosome 1p31. Replication was obtained in
the index paper in a Jewish ancestry case-
control analysis of patients with Crohn’s
disease by transmission disequilibrium testing
in 883 families with offspring affected by IBD
and in a combined case-control analysis of
these three cohorts (IBD, p = 6.62E-19).
IL-23 is a pivotal cytokine in the differentia-
tion of T helper cells, especially their differ-
entiation into Th17 T cells.4 Although the Th17
T cell subset has been shown to mediate
chronic and autoimmune inflammatory condi-
tions in animal models, clear evidence exists
for the central role of IL-23 in the development
of intestinal disease.5–7
Both Crohn’s disease and ulcerative colitis
commonly first present during childhood and
adolescence and are associated with high
disease-related and treatment-related morbid-
ity in these young patients.8 Disease incidence
is high in our population, and in others in
Northern Europe in whom the NOD2/CARD15
contribution is small. These considerations,
together with well established epidemiological
data suggesting that early-onset disease has a
strong genetic basis, provide a clear scientific
rationale for performing molecular studies in
this group.
Our aim was to assess the contribution of the
Arg381Gln variant (rs11209026) of IL23R in
determining susceptibility and phenotype in
childhood onset IBD in Scotland. We also sought
to investigate the interaction between carriage of
any of the three common NOD2/CARD15 var-
iants and carriage of this IL23R variant in
determining susceptibility to Crohn’s disease.
A total of 1294 subjects comprising 358 with
IBD aged ,17 years at diagnosis (table 1), 594
parents and 342 controls were genotyped for
rs11209026 G/A using TaqMan (7900HT
sequence detection system; Applied Biosystems,
Foster City, California, USA). Allelic and geno-
type frequency comparisons between cases and
controls using x2 and transmission disequili-
brium testing were applied to assess the associa-
tion of IL23R rs11209026 with IBD. The three
common NOD2/CARD15 variants were geno-
typed as previously described.10
In cases and controls, rs11209026 was in
Hardy-Weinberg equilibrium. The allelic fre-
quency of rs11209026*A differed significantly
between IBD/Crohn’s disease cases and con-
trols (2.9%/3.0% vs 5.5%, p = 0.01, OR 0.51
(95% CI 0.30 to 0.88) and p = 0.04, OR 0.53
(95% CI 0.28 to 0.98); table 2).
The GG genotype was associated with an
increased risk of IBD/Crohn’s disease (p = 0.01,
OR 2.01 (95% CI 1.15 to 3.49) and p = 0.03, OR
1.96 (95% CI 1.03 to 3.70)). Analysis by
transmission disequilibrium testing showed sig-
nificant overtransmission of the G allele for IBD
(p = 0.004) and Crohn’s disease (p = 0.04), with
a trend towards significance in ulcerative colitis
hindered by a small number of informative
families with ulcerative colitis (table 3).
In Crohn’s disease there was no difference
(p = 0.94) in allelic frequency between NOD2/
CARD15 wild type and NOD2/CARD15 variant-
carrying patients. However, owing to the small
numbers of cases and controls carrying this
IL23R variant, our study was not adequately
powered to formally assess epistasis with NOD2/
CARD15. Genotype-phenotype analysis in
Crohn’s disease and ulcerative colitis based on
the Montreal classification did not demonstrate
any significant effect of IL23R rs11209026; speci-
fically, we were not able to show a protective
effect against ileal Crohn’s disease (p = 0.21).9
The successful identification of IL23R as a
novel IBD susceptibility gene has provided proof
of principle for the applicability of genome-wide
association studies in the genetics of complex
diseases. We show for the first time that IL23R
variation influences susceptibility to IBD and
Crohn’s disease, but not phenotype, in an
exclusively paediatric IBD cohort. The data
complement the results of the initial North
American study and the replication studies
currently underway in the UK adult population.10
However, the contribution of this IL23R allele to
IBD is not sufficiently strong to explain the high
incidence of childhood IBD in our or other
populations with a low NOD2/CARD15 contribu-
tion. Other determinants are likely to be involved
in Northern Europe.11 12 Genome-wide associa-
tion scanning has already provided other candi-
dates requiring rigorous analyses.13 14
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Table 1 Demographic data and
inflammatory bowel disease (IBD)
phenotype in patients diagnosed with
IBD at ,17 years of age based on
Montreal guidelines for classification
of Crohn’s disease/ulcerative colitis9
N 358
M/F 205/153
Median age at
diagnosis (Q1–Q3)
11.1 years
(8.6–12.9)
CD/UC/IBD type
unclassified
239/88/31
Caucasian 97%
Montreal CD location L1¡L4: 13;
L2¡L4: 81;
L3¡L4: 131;
L4: 3
Montreal CD behaviour B1(¡p): 214;
B2(¡p): 9;
B3(¡p): 9;
Bx(p): 27
Montreal UC extent E3: 63;
E2: 17;
E1: 4
CD, Crohn’s disease; UC, ulcerative colitis.
Crohn’s disease: L1, ileal; L2, colonic; L3,
ileocolonic; L4, upper gastrointestinal tract; B1,
not stricturing, not penetrating; B2, stricturing;
B3, penetrating; p, penetrating perianal.
Ulcerative colitis: E3, extensive colitis; E2, left-
sided colitis; E1, proctitis only.
Table 2 Interleukin-23 receptor (IL23R) rs11209026G/A (Arg381Gln) genotype
and allelic frequencies in controls and patients with inflammatory bowel disease
(IBD), Crohn’s disease (CD) and ulcerative colitis (UC) diagnosed ,17 years of age
Arg381Gln
IL23R Control IBD p Value CD p Value UC p Value
HWE 0.27 0.56 0.63 0.73
GG 304/342
(88.9%)
337/358
(94.1%)
0.01 219/233
(94.0%)
0.03 80/86
(93.0%)
0.25
GA 38/342
(11.1%)
21/358
(5.9%)
0.01 14/233
(6.0%)
0.03 6/86
(7.0%)
0.25
AA 0 0 0 0
Allele A 38/684
(5.5%)
21/716
(2.9%)
0.01 14/466
(3.0%)
0.04 6/172
(3.5%)
0.27
Hardy-Weinberg equilibrium (HWE) p values are given.
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JAK V617F missense mutation is
absent in pancreatic cancer
Aberrant constitutive activation of STAT3
(signal transducer and activator of transcrip-
tion) leads to cellular transformation and aids
tumorigenesis in pancreatic cancer and its
inhibition can lead to growth arrest.1–4 The
exact mechanism of this constitutive activation
has not been elucidated, although downstream
mediators may include ERK and p21 signal-
ling.1–4 Blocking JAK2 (Janus Kinase), a
known upstream activator of STAT3, by
AG490, a tryphostin inhibitor, reduced phos-
phorylation of STAT3 and produced compar-
able in vitro effects, suggesting a role for JAK2
in pancreatic carcinogenesis.3
JAK2 V617F missense mutation has recently
been shown by several independent groups to
play an important role in myeloproliferative
disorders5 as well as prothrombotic states such
as Budd-Chiari syndrome (which may be due
to latent myeloproliferative disorders).5 6 We
postulated that JAK2 V617F mutation may
play a role in pancreatic cancer, in which the
prothrombotic state is well recognised.
We analysed genomic DNA (all from
unstained slides of representative surgical
specimens) from 26 patients undergoing sur-
gery for various pancreatic diseases (table 1)
along with genomic DNA from 10 cell lines
(Panc1, Paca3, MiaPaCa2, Capan1 and 2, Suit2,
AsPc1, 818.4, Hpaf2, H766T) for JAK2 V617F
mutation using phenol-choloroform extraction
with ethanol precipitation, using appropriate
positive and negative controls as previously
described.6 Briefly, all cells (.70% tumour
tissue in cancer specimens, no microdissection)
were scraped from unstained slides into high
salt buffer and samples were made up to 200 ml
with proteinase K, RNase A and sodium
dodecyl sulfate, incubated at 37 C˚ overnight
before phenol extraction and ethanol precipita-
tion. Genomic DNA from cell lines was
extracted from 70% confluent million cells
using Trizol (Invitrogen Ltd, Paisley, UK)
reagent digestion followed by ethanol precipi-
tation. A highly sensitive allele-specific PCR
was used to detect the G to T mutation in exon
14 of JAK2 (corresponding to amino acid
position 617) as previously described.6 Briefly,
a three primer PCR was performed which, in
the absence of a mutation, produces an
internal amplification control band. Where a
mutation is present, an additional band is also
amplified and is specific to the mutant
sequence. The sensitivity of the assay is 1 cell
in 100, determined by mixing positive con-
trol genomic DNA (extracted from HEL cells)
with non-mutated genomic DNA. We have
previously validated this methodology by con-
ventional Sanger sequencing and pyrosequen-
cing.6 No such mutations were detected at the
JAK2 617 codon for pancreatic cancer or cell
samples.
We propose that STAT3 activation, as pre-
viously described in pancreatic cancer,1–4 is by
mechanisms other than constitutive activation
of JAK2 by missense mutation at the V617F
site. Similarly, while JAK2 mutation is absent
in acute myeloid leukaemia, STAT3 activation
is common and is being explored.7 In glioblas-
toma, for example, it has been suggested that
STAT3 is activated by exogenous interleukin
(IL)-4.8 IL-4 interacts with IL-13Ra2 receptor
and, although IL-13Ra2 does not bind with
STAT3 directly, it blocks STAT6 activation and
excludes this downstream event. Thus, IL-4
can have an anti-apoptotic effect in glioblas-
toma cells via STAT3 signalling. Conversely,
deletion of the SOC3 (suppressor of cytokine
signalling 3) gene in liver cancer9 and silencing
of the SHP1 gene (by methylation) in lym-
phoma10 can activate STAT3 signalling. It has
recently been suggested that there may be
novel mutations in exon 12 which may account
for a minority of patients with polycythemia
vera and idiopathic erythrocytosis, who are
Table 3 Interleukin-23 receptor (IL23R) rs11209026G/A (Arg381Gln)
transmission disequilibrium testing in trios with childhood onset IBD
Arg381Gln
IL23R
Informative families
(n)
Transmissions
observed
Transmissions
expected p Value
IBD 34 59 50.5 0.004
CD 23 39 34 0.04
UC 9 16 13.5 0.09
Assessed using FBAT software Version 1.7.3 available from http://www.biostat.harvard.edu/,fbat/
fbat.htm.
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis.
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